Log in to search using one of your social media accounts:

 

FDA OKs Biologic Guselkumab (Tremfya) for Plaque Psoriasis FDA OKs Biologic Guselkumab (Tremfya) for Plaque Psoriasis

Guselkumab is the first and only approved biologic agent that selectively blocks interleukin-23, a key player in plaque psoriasis.FDA Approvals
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Dermatology News Alert Source Type: news

Related Links:

We report the case of a 68-year-old man with Crohn's disease, who developed  disseminated tuberculosis due to anti-TNF-α immunosuppressive therapy. The diagnosis was based on the histopathological findings and molecular biology assays.We discuss the clinical presentation and workup of this case, and we present a comparative analysis of tuberculosis cases associated with anti-TNF-α reported in Colombia during the last 10 years emphasizing on the diagnosis and treatment of latent tuberculosis. PMID: 29668128 [PubMed - in process]
Source: Biomedica : Revista del Instituto Nacional de Salud - Category: International Medicine & Public Health Tags: Biomedica Source Type: research
ZURICH (Reuters) - Swiss drugmaker Novartis' first quarterly results under new CEO Vas Narasimhan have been marred by a prized psoriasis treatment that disappointed and a sharp slump in sales by its U.S. generics unit.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news
Kallikrein-related peptidase 6 (KLK6) is a serine protease hypothesized to promote inflammation via cleavage of protease-activated receptors PAR1 and PAR2. KLK6 and PAR1/2 are expressed in skin, however their biological roles remain unclear. RNAseq of lesional skin from psoriasis (Ps) patients identified KLK6 as the most-increased KLK family member (n=6; 13-fold; P
Source: Journal of Investigative Dermatology - Category: Dermatology Authors: Tags: Adaptive and Auto-Immunity Source Type: research
Biologics are effective for the treatment of psoriasis, but head-to-head studies comparing the efficacy of the recently approved biologics are lacking for certain comparators of interest. Here, we indirectly compared psoriasis clinical trial efcacy data between ixekizumab (IXE), a selective interleukin (IL)-17A antagonist,and guselkumab (GUS), a recently approved IL-23 p19 inhibitor. We used the adjusted indirect comparison (AIC) Bucher method (BU) and two modied Signorovitch methods (SG) matching for overall or adjusting for baseline characteristics and effect modifiers to compare IXE 80 mg every 2 weeks (IXEQ2W) to GUS 1...
Source: Journal of Investigative Dermatology - Category: Dermatology Authors: Tags: Adaptive and Auto-Immunity Source Type: research
Psoriasis is a chronic skin disorder that is characterized by excessive skin inflammation with scaly erythema and epidermal thickness. Epithelial cell adhesion molecule (EpCAM) is a cell surface protein that is expressed by Langerhans cells (LCs), a population of epidermal dendritic cells, and normal epithelial cells. LCs control initial immune response to antigen or pathogen and therefore we hypothesized that EpCAM expressed by LC might be important in regulating inflammatory immune responses. Mutations in EpCAM have been reported in patients with congenital tufting enteropathy (CTE), who suffer from severe diarrhea and E...
Source: Journal of Investigative Dermatology - Category: Dermatology Authors: Tags: Adaptive and Auto-Immunity Source Type: research
Type 1 regulatory T (Tr1) cells, are Foxp3- IL-10-secreting regulatory T cells implicated as key regulators of peripheral immune tolerance. Recently it was identified that surface expression of CD49b and LAG-3 is sufficient to identify this specific cell lineage. As IL-10 and LAG-3 expression in psoriasis lesions are extremely low, we hypothesized that impaired immune tolerance in psoriasis could be associated with reduced Tr1 cells. To test the hypothesis, we analyzed 12 psoriasis patients' blood&skin tissues, and 8 control blood samples to compare Tr1(CD3+ CD4+ CD8- CD49b+ LAG-3+) cells, Tregs(CD3+ CD4+ CD8- CD25+ CD...
Source: Journal of Investigative Dermatology - Category: Dermatology Authors: Tags: Adaptive and Auto-Immunity Source Type: research
In this study, we investigated the effects of lipopolysaccharides (LPS) and interleukin (IL)-17A on the activation of macrophages in in vivo mouse skin. We examined whether macrophages are activated in the skin of imiquimod (IMQ)-treated mice, a model for IL-17A-induced psoriasis-like skin inflammation, and flaky-tail (Flgft) mice, a model for IL-17A-induced chronic atopic dermatitis-like skin inflammation.
Source: Journal of Investigative Dermatology - Category: Dermatology Authors: Tags: Adaptive and Auto-Immunity Source Type: research
Nearly a third of patients with psoriasis (PsO) develop psoriatic arthritis (PsA) at some point in their life. PsA is a debilitating condition that affects the joints, particularly in the fingers and toes and is known to significantly lower patients ’ quality-of-life. As PsA is characterized by a diverse set of clinical features, referral to a qualified rheumatologist, valid diagnosis, and effective treatment is often delayed. It is now known that a delay in treatment of even 6 months may result in irreparable joint damage.
Source: Journal of Investigative Dermatology - Category: Dermatology Authors: Tags: Adaptive and Auto-Immunity Source Type: research
Pustular psoriasis is a rare autoinflammatory skin disease characterised by the appearance of small sterile pustules on inflamed skin. The disease can be classified into three sub-types. Generalised pustular psoriasis (GPP) is an acute condition with widespread pustulation. Acrodermatitis continua of Hallopeau (ACH) and palmoplantar pustular psoriasis (PPP) are chronic and localised diseases affecting the nail apparatus (ACH), or the palms and/or soles. Mutations in IL36RN and AP1S3 have been associated with a proportion of pustular psoriasis cases, but the rarity of the disease has hindered attempts to study correlations ...
Source: Journal of Investigative Dermatology - Category: Dermatology Authors: Tags: Clinical Research: Epidemiology of Skin Diseases Source Type: research
Psoriasis is a chronic inflammatory skin disorder which has been reported to be associated with cardiometabolic comorbidities in Caucasians. However, the association between psoriasis and risk of atherosclerotic cardiovascular disease (ASCVD) among Asians is largely unclear yet. 1,733,620 Koreans who received health insurance from the National Health Insurance System and had a medical evaluation every two years between 1997-2000 were prospectively followed. The point prevalence of psoriasis was 0.42% and 0.35% among Korean men and women, respectively and there was an age-dependent increase in psoriasis prevalence among men.
Source: Journal of Investigative Dermatology - Category: Dermatology Authors: Tags: Clinical Research: Epidemiology of Skin Diseases Source Type: research
More News: Dermatology | Health | Psoriasis | Skin